Andrea Saglietto1, Roberto De Ponti2, Luigi Di Biase3, Mario Matta4, Fiorenzo Gaita5, Jorge Romero3, Gaetano M De Ferrari1, Matteo Anselmino1. 1. Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy. 2. Department of Heart and Vessels, Ospedale di Circolo & Macchi Foundation, University of Insubria, Varese, Italy. 3. Cardiac Arrhythmia Center, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. 4. Division of Cardiology, Sant'Andrea Hospital, Vercelli, Italy. 5. Cardiovascular Department, Clinica Pinna Pintor, Policlinico di Monza, Turin, Italy.
Abstract
BACKGROUND: The impact of atrial fibrillation catheter ablation (AFCA) on hard clinical endpoints remains controversial. OBJECTIVE: Our aim was to conduct a random-effect model meta-analysis on efficacy data from high-quality large matched database/registry studies and randomized clinical trials. We compared long-term all-cause mortality, stroke, and hospitalization for heart failure in patients undergoing AFCA vs patients treated with medical therapy alone (rhythm and/or rate control medications) in a general AF population. METHODS AND RESULTS: PubMed/MEDLINE and Embase databases were screened and a total of nine studies were selected (one randomized clinical trial-CABANA-and eight large matched population studies). A total of 241 372 patients (27 711 in the ablation group, 213 661 in the nonablation group) were included. After a median follow-up of 3.5 years, AFCA decreased the risk of mortality (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.54-0.72; I2 = 54%; number needed to treat [NNT] = 28), stroke (HR, 0.63; 95% CI, 0.56-0.70; I2 = 23%; NNT = 59) and hospitalization for heart failure (HR, 0.64; 95% CI, 0.51-0.80; I2 = 28%; NNT = 33) compared with AF patients treated with medical therapy alone. CONCLUSION: Based on the currently available efficacy and effectiveness evidence, AFCA significantly reduces the risk of death, stroke, and hospitalization compared with medical therapy alone.
BACKGROUND: The impact of atrial fibrillation catheter ablation (AFCA) on hard clinical endpoints remains controversial. OBJECTIVE: Our aim was to conduct a random-effect model meta-analysis on efficacy data from high-quality large matched database/registry studies and randomized clinical trials. We compared long-term all-cause mortality, stroke, and hospitalization for heart failure in patients undergoing AFCA vs patients treated with medical therapy alone (rhythm and/or rate control medications) in a general AF population. METHODS AND RESULTS: PubMed/MEDLINE and Embase databases were screened and a total of nine studies were selected (one randomized clinical trial-CABANA-and eight large matched population studies). A total of 241 372 patients (27 711 in the ablation group, 213 661 in the nonablation group) were included. After a median follow-up of 3.5 years, AFCA decreased the risk of mortality (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.54-0.72; I2 = 54%; number needed to treat [NNT] = 28), stroke (HR, 0.63; 95% CI, 0.56-0.70; I2 = 23%; NNT = 59) and hospitalization for heart failure (HR, 0.64; 95% CI, 0.51-0.80; I2 = 28%; NNT = 33) compared with AFpatients treated with medical therapy alone. CONCLUSION: Based on the currently available efficacy and effectiveness evidence, AFCA significantly reduces the risk of death, stroke, and hospitalization compared with medical therapy alone.
Authors: Matteo Anselmino; Stefania Scarsoglio; Luca Ridolfi; Gaetano Maria De Ferrari; Andrea Saglietto Journal: Front Cardiovasc Med Date: 2022-09-14